Lifecore Biomedical Inc Dossier - Source-backed chat

Lifecore Biomedical Inc

LFCRNASDAQ

SectorHealth Care

IndustryLife Sciences Tools & Services

Beta (adjusted)1.07

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $6.53Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $247.5M

Enterprise Value $341.8M

Shares Outstanding 37.9M diluted

Next Earnings Date3 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Lifecore Biomedical has successfully completed its transition into a pure-play, US-based contract development and manufacturing organization (CDMO) specializing in complex sterile injectables. Following the divestiture of its legacy lower-margin food businesses and the resolution of its historical FDA warning letter, the company is highly leveraged to strong industry tailwinds, including the global demand for fill-finish capacity (driven by GLP-1s and complex biologics) and supply chain onshoring. While trailing financials reflect heavy turnaround investments and near-term customer transitions, Lifecore's newly expanded $300 million capacity is highly underutilized at ~20%, providing a massive runway for margin expansion. The rapid addition of seven late-stage pipeline programs and commercial site transfers within the last seven months validates its revamped commercial strategy and underpins a clear path toward its 2029 target of a 12% revenue CAGR and >25% EBITDA margins.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$5.00

Mean target$6.75

High · most bullish analyst$9.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.0015%

Delays in technical transfers or regulatory approvals for pipeline programs postpone commercial manufacturing revenues. The company faces difficulties refinancing its $50.2 million Series A preferred stock redemption exposure under favorable terms, leading to dilution or liquidity constraints. Continued customer inventory work-downs or the loss of a major customer further depresses near-term capacity utilization, keeping EBITDA margins compressed.

Base CaseCentral scenario

$6.8360%

Lifecore executes steadily on its pipeline, with signed commercial site transfers generating commercial revenues within the projected 24-month window. Revenue for 2026 lands within the guided range of $120 million to $125 million, and Adjusted EBITDA reaches $20.5 million to $25 million. The company successfully manages its Series A preferred stock redemption exposure through structured refinancing, and capacity utilization climbs gradually, supporting long-term progress toward the 12% revenue CAGR target.

Bull CaseUpside scenario

$9.0025%

Accelerated onboarding of late-stage pipeline programs and rapid commercialization of the newly signed GLP-1 and aesthetics site transfers drive capacity utilization toward 40% ahead of schedule. Strong demand for sterile injectables allows Lifecore to command premium pricing, pushing EBITDA margins past the 25% target by 2028. A successful resolution or refinancing of the Series A preferred stock removes the primary balance sheet overhang, leading to a significant valuation re-rating toward peer CDMO multiples.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Pure-play CDMO exposure to high-barrier sterile injectables and premium hyaluronic acid (HA) manufacturing.
Significant operating leverage with $90 million in recent growth capex enabling a $300 million revenue capacity on a highly underutilized (~20%) footprint.
Strong commercial momentum with seven late-stage pipeline additions signed in a seven-month period.
Favorable macro tailwinds from supply chain onshoring, FDA drug shortage lists, and global fill-finish capacity constraints.

Key Investment Risks

Near-term balance sheet pressure from the $50.2 million Series A preferred stock redemption exposure.
High customer concentration, historically tied to major accounts like Alcon.
Execution risks associated with the technical transfer timelines (typically 24 months) before commercial revenues materialize.
Unprofitability on a GAAP basis during the current transition and turnaround phase.

Thesis Invalidation Triggers

Failure to refinance or extend the Series A preferred stock redemption terms, leading to severe liquidity distress.
A material regulatory setback or negative FDA inspection finding at its manufacturing facilities.
Termination or significant volume reduction in the take-or-pay agreement with its primary customer, Alcon.
A prolonged delay in technical transfers that prevents signed programs from transitioning to commercial manufacturing within 24 months.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.